Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 24 (6), 1280-97

Frequency Estimator for Assessing of Follow-On Biologics


Frequency Estimator for Assessing of Follow-On Biologics

Ying Lu et al. J Biopharm Stat.


For approval of generic drugs, the U.S. Food and Drug Administration (FDA) requires the evidence of bioequivalence in average bioavailability be provided. This is based on the Fundmental Bioequivalence Assumption from FDA that if two drug products are shown to be bioequivalent, it is assumed that they are therapeutically equivalent and can be used interchangeably. Recently, there are a few statistical considerations for assessing biosimilarity. In this article, we propose a new method based on a frequency estimator to evaluate biosimilarity; the large sample properties of the estimator, the power analysis, and calculation of the sample size are considered. Under a three-arm parallel design, the power comparison between the frequency estimator method and the other existing methods is studied through simulation, and the statistical test based on the proposed method is more powerful than for the other two methods. Simultaneously, we compared the relative performance of the three methods, and the empirical consistency and inconsistency probability are obtained in evaluating the biosimilarity.

Keywords: Bioequivalent; Biosimilarity; Consistency; Frequency estimator method; Three-arm parallel design.

Similar articles

See all similar articles

Publication types

MeSH terms

LinkOut - more resources